HopeStage
Back to all studies
CompletedNCT00505765

NAP for cognitive difficulties in schizophrenia

About this titleRead the official source — NCT00505765
Medication studyAges 18–60United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 60 years.

Listed locations
Los Angeles and 7 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2007
Recruitment status
Completed
Enrollment listed in the registry
63
Sponsor
University of California, Los Angeles
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT00505765
Official title
Show the full official title

A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Angeles · Catonsville · Boston

4 more locations
  • St Louis
  • New York
  • Orangeburg
  • Durham

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of California, Los Angeles, a university.

Did this study involve medication?

Yes. The study involved medication, including AL-108 and Placebo.

Who was this study for?

Listed age limits: 18 years to 60 years.

Want to explore more studies?

Explore studies